These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 26369347)

  • 21. Can we afford to offer pre-exposure prophylaxis to MSM in Catalonia? Cost-effectiveness analysis and budget impact assessment.
    Reyes-Urueña J; Campbell C; Diez E; Ortún V; Casabona J
    AIDS Care; 2018 Jun; 30(6):784-792. PubMed ID: 29262694
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preexposure prophylaxis for men who have sex with men in the Netherlands: impact on HIV and Neisseria gonorrhoeae transmission and cost-effectiveness.
    Reitsema M; Hoek AJV; van der Loeff MS; Hoornenborg E; van Sighem A; Wallinga J; van Benthem B; Xiridou M
    AIDS; 2020 Mar; 34(4):621-630. PubMed ID: 31895142
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness of pre-exposure prophylaxis for HIV prevention in men who have sex with men in the UK: a modelling study and health economic evaluation.
    Cambiano V; Miners A; Dunn D; McCormack S; Ong KJ; Gill ON; Nardone A; Desai M; Field N; Hart G; Delpech V; Cairns G; Rodger A; Phillips AN
    Lancet Infect Dis; 2018 Jan; 18(1):85-94. PubMed ID: 29054789
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Translating PrEP effectiveness into public health impact: key considerations for decision-makers on cost-effectiveness, price, regulatory issues, distributive justice and advocacy for access.
    Hankins C; Macklin R; Warren M
    J Int AIDS Soc; 2015; 18(4 Suppl 3):19973. PubMed ID: 26198343
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The cost-effectiveness of HIV pre-exposure prophylaxis in men who have sex with men and transgender women at high risk of HIV infection in Brazil.
    Luz PM; Osher B; Grinsztejn B; Maclean RL; Losina E; Stern ME; Struchiner CJ; Parker RA; Freedberg KA; Mesquita F; Walensky RP; Veloso VG; Paltiel AD
    J Int AIDS Soc; 2018 Mar; 21(3):e25096. PubMed ID: 29603888
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluating the potential impact and cost-effectiveness of dapivirine vaginal ring pre-exposure prophylaxis for HIV prevention.
    Reidy M; Gardiner E; Pretorius C; Glaubius R; Torjesen K; Kripke K
    PLoS One; 2019; 14(6):e0218710. PubMed ID: 31242240
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The cost-effectiveness of oral HIV pre-exposure prophylaxis and early antiretroviral therapy in the presence of drug resistance among men who have sex with men in San Francisco.
    Shen M; Xiao Y; Rong L; Meyers LA; Bellan SE
    BMC Med; 2018 Apr; 16(1):58. PubMed ID: 29688862
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effectiveness and cost effectiveness of oral pre-exposure prophylaxis in a portfolio of prevention programs for injection drug users in mixed HIV epidemics.
    Alistar SS; Owens DK; Brandeau ML
    PLoS One; 2014; 9(1):e86584. PubMed ID: 24489747
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Portfolios of biomedical HIV interventions in South Africa: a cost-effectiveness analysis.
    Long EF; Stavert RR
    J Gen Intern Med; 2013 Oct; 28(10):1294-301. PubMed ID: 23588668
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Agent-based model projections for reducing HIV infection among MSM: Prevention and care pathways to end the HIV epidemic in Chicago, Illinois.
    Vermeer W; Gurkan C; Hjorth A; Benbow N; Mustanski BM; Kern D; Brown CH; Wilensky U
    PLoS One; 2022; 17(10):e0274288. PubMed ID: 36251657
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Cost-effectiveness of Human Immunodeficiency Virus (HIV) Preexposure Prophylaxis and HIV Testing Strategies in High-risk Groups in India.
    Kazemian P; Costantini S; Kumarasamy N; Paltiel AD; Mayer KH; Chandhiok N; Walensky RP; Freedberg KA
    Clin Infect Dis; 2020 Feb; 70(4):633-642. PubMed ID: 30921454
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Optimizing HIV/AIDS resources in Armenia: increasing ART investment and examining HIV programmes for seasonal migrant labourers.
    Kelly SL; Shattock AJ; Kerr CC; Stuart RM; Papoyan A; Grigoryan T; Hovhannisyan R; Grigoryan S; Benedikt C; Wilson DP
    J Int AIDS Soc; 2016; 19(1):20772. PubMed ID: 27281790
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A cost-effectiveness analysis of HIV preexposure prophylaxis for men who have sex with men in Australia.
    Schneider K; Gray RT; Wilson DP
    Clin Infect Dis; 2014 Apr; 58(7):1027-34. PubMed ID: 24385445
    [TBL] [Abstract][Full Text] [Related]  

  • 34. PrEP for key populations in combination HIV prevention in Nairobi: a mathematical modelling study.
    Cremin I; McKinnon L; Kimani J; Cherutich P; Gakii G; Muriuki F; Kripke K; Hecht R; Kiragu M; Smith J; Hinsley W; Gelmon L; Hallett TB
    Lancet HIV; 2017 May; 4(5):e214-e222. PubMed ID: 28233660
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The new role of antiretrovirals in combination HIV prevention: a mathematical modelling analysis.
    Cremin I; Alsallaq R; Dybul M; Piot P; Garnett G; Hallett TB
    AIDS; 2013 Jan; 27(3):447-58. PubMed ID: 23296196
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-Effectiveness of HIV Pre-exposure Prophylaxis Among Heterosexual Men in South Africa: A Cost-Utility Modeling Analysis.
    Vogelzang M; Terris-Prestholt F; Vickerman P; Delany-Moretlwe S; Travill D; Quaife M
    J Acquir Immune Defic Syndr; 2020 Jun; 84(2):173-181. PubMed ID: 32141959
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PrEP as a feature in the optimal landscape of combination HIV prevention in sub-Saharan Africa.
    McGillen JB; Anderson SJ; Hallett TB
    J Int AIDS Soc; 2016; 19(7(Suppl 6)):21104. PubMed ID: 27760682
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The potential impact of pre-exposure prophylaxis for HIV prevention among men who have sex with men and transwomen in Lima, Peru: a mathematical modelling study.
    Gomez GB; Borquez A; Caceres CF; Segura ER; Grant RM; Garnett GP; Hallett TB
    PLoS Med; 2012; 9(10):e1001323. PubMed ID: 23055836
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness analysis of pre-exposure prophylaxis for HIV-1 prevention in the Netherlands: a mathematical modelling study.
    Nichols BE; Boucher CAB; van der Valk M; Rijnders BJA; van de Vijver DAMC
    Lancet Infect Dis; 2016 Dec; 16(12):1423-1429. PubMed ID: 27665989
    [TBL] [Abstract][Full Text] [Related]  

  • 40. HIV pre-exposure prophylaxis and early antiretroviral treatment among female sex workers in South Africa: Results from a prospective observational demonstration project.
    Eakle R; Gomez GB; Naicker N; Bothma R; Mbogua J; Cabrera Escobar MA; Saayman E; Moorhouse M; Venter WDF; Rees H;
    PLoS Med; 2017 Nov; 14(11):e1002444. PubMed ID: 29161256
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.